Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00p -0.85% 116.50p 95,115 16:28:41
Bid Price Offer Price High Price Low Price Open Price
115.00p 118.00p 122.00p 116.50p 117.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -18.72 -67.54 36.1

Faron Pharma (FARN) Latest News

More Faron Pharma News
Faron Pharma Takeover Rumours

Faron Pharma (FARN) Share Charts

1 Year Faron Pharma Chart

1 Year Faron Pharma Chart

1 Month Faron Pharma Chart

1 Month Faron Pharma Chart

Intraday Faron Pharma Chart

Intraday Faron Pharma Chart

Faron Pharma (FARN) Discussions and Chat

Faron Pharma Forums and Chat

Date Time Title Posts
16/10/201815:58Respite for ARDS sufferers1,047

Add a New Thread

Faron Pharma (FARN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:29:06115.90373432.31O
15:28:28116.20667775.05O
15:26:14116.25750871.85O
15:25:57119.008,3989,993.62O
15:25:21119.00833991.27O
View all Faron Pharma trades in real-time

Faron Pharma (FARN) Top Chat Posts

DateSubject
19/10/2018
09:20
Faron Pharma Daily Update: Faron Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharma was 117.50p.
Faron Pharma has a 4 week average price of 99.50p and a 12 week average price of 69.50p.
The 1 year high share price is 915p while the 1 year low share price is currently 51p.
There are currently 31,027,894 shares in issue and the average daily traded volume is 77,619 shares. The market capitalisation of Faron Pharma is £36,147,496.51.
28/6/2018
07:51
b1tcoin: LSE:FARN Faron Pharma Share News (FARN) 4 Follow FARN Share Name Share Symbol Market Type Share ISIN Share Description Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI) Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade +5.50p +8.66% 69.00p 67.00p 71.00p - - - 0 07:30:01 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 0.0 -18.7 -67.5 - 21.41 Print Alert Faron Pharmaceuticals Oy Clevegen successful toxicity studies 28/06/2018 7:01am RNS Non-Regulatory TIDMFARN Faron Pharmaceuticals Oy 28 June 2018 Faron Pharmaceuticals Ltd ("Faron" or the "Company") Clevegen shows good safety and potential to block Clever-1 on circulating monocytes -- Wholly-owned Clevegen (FP-1305) shows no toxicity in dose escalation studies in large preclinical models -- The no-observed-adverse-effect-level (NOAEL) was 100 mg/kg, which is roughly 30 times higher concentration than needed for Clever-1 occupancy in vivo -- Clevegen also blocked Clever-1 on circulating monocytes as expected. The duration of blocking was dose dependent and resumed to normal level in 20 days in the highest dose -- The Company expects CTA filing for MATINS study in Q3 2018 and first patient recruitment in Q4 2018 TURKU - FINLAND, 28 June 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, today announces successful toxicity studies and control of blood Clever-1 positive monocytes, precursor cells to tumour associated macrophages (TAM) in large preclinical models. The toxicity studies were designed to fulfil regulatory requirements for 3-week interval intravenous administration of Clevegen, typical for other anti-cancer antibodies currently in use. FP-1305 is a humanized IgG4 monoclonal antibody produced in CHO -cells by Faron collaborator Abzena. The FP-1305 drug product in its final formulation was administered as a single dose at 3, 30 and 100 mg/kg. No toxicologically relevant changes were observed in any subject. No major changes were observed after treatment with FP-1305 in T lymphocytes subsets. The binding of Clevegen to its receptor on circulating CD14+ monocytes was confirmed by investigating the receptor occupancy, the recovery of which occurred between 3 to 20 days after dosing in a dose-dependent manner. No relevant changes were present in cytokines and no anti-drug antibodies (ADA) were detected in any subject. Therefore, the highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL). Dr Markku Jalkanen, CEO of Faron, said: "We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen and the high NOAEL concentration. We were also delighted to learn that Clevegen administration blocks Clever-1 on circulating monocytes, which are one group of our target cells in our MATINS Phase I/II clinical trial. Our plan is now to file the MATINS clinical trial application (CTA) during Q3 2018 and, as previously announced, initiate this first Clevegen human trial in Q4 2018." About MATINS trial: MATINS study is first-in-human open label Phase I/II adaptive clinical trial in selected metastatic or inoperable solid tumours to investigate the safety and efficacy of Clevegen (FP-1305). The selected tumours are cutaneous melanoma, hepatobiliary, pancreatic, ovarian or colorectal cancer, which are all known to contain high amounts of Clever-1 positive TAMs. The trial is to be run in three parts. Part I will be conducted to determine the safe and tolerable dose of Clevegen, which will then be used in Part II to expand the cohorts of individual tumour types. Part III of the trial aims to confirm the efficacy of Clevegen with the cohorts selected based on Part II. For more information please contact:
22/6/2018
13:13
craigo121: You could argue Director(non exec) buying 48k better than selling his quite considerable stash!! OVER 1 MILLION# Bet he wishes sold few months ago!! The 50k buy looks to me like a desperate attempt into showing confidence in an already depleted share price.
18/6/2018
18:21
ic0gcds00: It hurts to see the share price plummet so much after an £8 placingThe board need to man up and come up with some positves for dhareholders
13/6/2018
18:19
alamaison5: The cash? Just did a placing...and at a much higher price than the share price is now... Imagine the face of the investors when the price crashed. Shouldn't they average down, lol...
04/6/2018
10:26
kirk 6: I did see that share price should be north of £8 now
15/5/2018
10:45
craigo121: 90% drop in share price does not make a bargain! It's dropped 90% for a reason the drug failed they spent 30 million developing not much left in the coffers apart from the 2nd drug 5 million development should equate to 50-60p per share
10/5/2018
15:16
bangers and cash1: Placebo makers, don’t know who to trust some random guy with a short or institutions who decided to buy at many multiples of the share price. Hmmm. Also how can you claim people are ramping when you are flat out lying and posting over and over again, clearly trying to scare people into selling to suit your short. Please leave.
09/5/2018
20:45
deltalo: The bounce has happened but like a bouncing ball the heigh's get lower with each bounce. There is no income to pay for any new trials let alone pay for the rest of the last one. The whole inflation in the share price was on the back of a positive outcome from this trial from the start. What I would like to know is where's the funding coming from and if there is any new trials, how much and how many years will it take. I know something and that's I'm not waiting and I'm not paying. This will fall to its real worth.
03/5/2018
15:35
allonblack: This is so predictable. CEO mouths off in london post period end about trial results on 8 May and then suddenly the share price week before is nothing to see here move along. Buy the dip.
06/4/2018
11:11
paxman: Breq from over at Stocko attended. She said: Some interesting things not obvious from the presentation. Company estimates trial results by May 8. That's the date final 2017 results are announced. Obviously just a target as we all know trial results can be delayed. Mention of further share price gains possible soon. Said in a controlled but positive way. i.e. company still optimistic on trial results. 100,000 treatments available by mid 2019 because company expects demand to be that high. How could doctors not use Traumakine if effective? Breq scanned the Faron website/Linkedin etc. New appointments with a focus on delivering Traumakine so Faron still confident.
Faron Pharma share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20181019 18:29:18